Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance

Table 1 Baseline demographics and clinical characteristics (n = 965)

Background factor	Category	n (%)
Sex	Male	378 (39.2%)
	Female	587 (60.8%)
Age	mean ± SD	35.4 ± 14.27
	< 18 yr	72 (7.5%)
	18 yr	892 (92.5%)
Height (cm)	mean ± SD	166.1 ± 7.97
Weight (kg)	mean ± SD	66.0 ± 13.86
Months since onset of first episode	mean ± SD	92.6 ± 113.95
Months since onset of current episode	mean ± SD	5.8 ± 55.52
Baseline BPRS score	mean ± SD	43.6 ± 15.28
Comorbidity of mental disorder besides schizophrenia	Yes	958 (99.3%)
Comorbidity besides mental disorder	Yes	848 (88.1%)
Antipsychotic medication within 1 mo prior to baseline	Yes	532 (55.3%)

BPRS: Brief psychiatric rating scale.